Hostname: page-component-5b777bbd6c-ks5gx Total loading time: 0 Render date: 2025-06-18T10:17:04.701Z Has data issue: false hasContentIssue false
  • English
  • Français

Complex atrial arrhythmias as first manifestation of catecholaminergic polymorphic ventricular tachycardia: an unusual course in a patient with a new mutation in ryanodine receptor type 2 gene

Published online by Cambridge University Press:  28 August 2013

Wolfgang Lawrenz ,
Otto N. Krogmann  and
Marcus Wieczorek
Wolfgang Lawrenz*
Affiliation:
Clinic for Pediatric Cardiology, Congenital Heart Disease, Heart Center Duisburg, Duisburg, Germany Clinic for Electrophysiology, Evangelic Hospital Dinslaken, Dinslaken, Germany
Otto N. Krogmann
Affiliation:
Clinic for Pediatric Cardiology, Congenital Heart Disease, Heart Center Duisburg, Duisburg, Germany
Marcus Wieczorek
Affiliation:
Clinic for Electrophysiology, Evangelic Hospital Dinslaken, Dinslaken, Germany
*
Correspondence to: W. Lawrenz, MD, Clinic for Pediatric Cardiology, Congenital Heart Disease, Heart Center Duisburg, Gerrickstr. 21, 47137 Duisburg, Germany. Tel: 0049-203-4513301; fax: 0049-203-4513303; E-mail: wolfgang.lawrenz@evkln.de
Get access Rights & Permissions [Opens in a new window]

Abstract

Catecholaminergic polymorphic ventricular tachycardia is a rare life-threatening arrhythmogenic disorder. An association with paroxysmal atrial fibrillation and other atrial arrhythmias has been described, but in all published cases the initial manifestation of the disease was ventricular arrhythmia. This is the first report about a patient who presented with complex atrial tachycardia and sinus node dysfunction about 1 year before the typical ventricular arrhythmias were observed, leading to the diagnosis of catecholaminergic polymorphic ventricular tachycardia. In this girl, a mutation of the ryanodine receptor type 2 gene, which has not been described so far, was discovered.

Keywords

Catecholaminergic polymorphic ventricular tachycardiaatrial fibrillationryanodine receptor type 2
Type
Brief Reports
Information
Cardiology in the Young , Volume 24 , Issue 4 , August 2014 , pp. 741 - 744
Copyright
Copyright © Cambridge University Press 2013 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1. Leenhardt, A, Lucet, V, Denjoy, I, Grau, F, Ngoc, DD, Coumel, P. Catecholaminergic polymorphic ventricular tachycardia in children: a 7-year follow-up of 21 patients. Circulation 1995; 91: 1512–1519.Google Scholar
2. Sumitomo, N, Harada, K, Nagashima, M, et al. Catecholaminergic polymorphic ventricular tachycardia: electrocardiographic characteristics and optimal therapeutic strategies to prevent sudden death. Heart 2003; 89: 66–70.Google Scholar
3. Priori, SG, Napolitano, C, Tiso, N, et al. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. Circulation 2001; 103: 196–200.Google Scholar
4. Hayashi, M, Denjoy, I, Extramiana, F, et al. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia. Circulation 2009; 119: 2426–2434.CrossRefGoogle ScholarPubMed
5. Postma, AV, Denjoy, I, Kamblock, J, et al. Catecholaminergic polymorphic ventricular tachycardia: RYR2 mutations, bradycardia, and follow up of the patients. J Med Genet 2005; 42: 863–870.Google Scholar
6. Sumitomo, N, Sakurada, H, Taniguchi, K, et al. Association of atrial arrhythmia and sinus node dysfunction in patients with catecholaminergic polymorphic ventricular tachycardia. Circ J 2007; 71: 1606–1609.Google Scholar
7. Pizzale, S, Gollob, MH, Gow, R, Birnie, DH. Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation. J Cardiovasc Electrophysiol 2008; 19: 1319–1321.CrossRefGoogle Scholar
8. Kazemian, P, Gollob, MH, Pantano, A, Oudit, GY. A novel mutation in the RYR2 gene leading to catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation: dose-dependent arrhythmia-event suppression by beta-blocker therapy. Can J Cardiol 2011; 27: e7–e10.CrossRefGoogle ScholarPubMed
9. Jiang, D, Xiao, B, Yang, D, et al. RYR2 mutations linked to ventricular tachycardia and sudden death reduce the threshold for store-overload-induced Ca2+ release (SOICR). PNAS 2004; 101: 13062–13067.Google Scholar
10. Vest, JA, Xander, HT, Wehrens, SRR, et al. Defective cardiac ryanodine receptor regulation during atrial fibrillation. Circulation 2005; 111: 2025–2032.Google Scholar